In a story written by investigative journalists Tomer Ganon and Dror Reich for Israeli technology news site, CTech, the authors report that Israeli Securities Authority (ISA) conducted a search of the offices of surgical robotics company Mazor Robotics Ltd seven months ago in May 2017.
Mazor Subject to Israeli Securities Investigation
1 min read Premium comments
Secondary
According to the CTech article, it was not until early December 2017 that Mazor received permission from the ISA to disclose the investigation and to confirm that the subject matter of the investigation was possible insider stock trading by third parties.
The issue appears to be trading in Mazor stock in and around the time of the May 2016 announcement of an investment and distribution deal with Medtronic.
As part of the May 2017 search of Mazor’s offices, Ori Hadomi, Mazor’s Chief Executive Officer, was reportedly questioned.
According to the company, there has been no further questioning of Mr. Hadomi and he is fully cooperating with the ISA.
The board of directors of Mazor have expressed their full support and confidence in Mr. Hadomi and in his continuous leadership of the company and its development.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.